866-997-4948(US-Canada Toll Free)

Diabetes & Obesity Drug Development Pipeline Review, 2016

Published By :

GBI Research

Published Date : Dec 2016

Category :

Diabetes

No. of Pages : 560 Pages

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.

Scope

  • Which companies are the most active within the pipeline for diabetes and obesity?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have occurred in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Table of Contents

Table of Contents
List of Tables
List of Figures
Diabetes and Obesity Report Coverage
Type 1 Diabetes (Juvenile Diabetes) Overview
Type 2 Diabetes Overview
Obesity Overview
Therapeutics Development by Stage
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Therapeutics under Development by Companies
Type 1 Diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Therapeutics under Investigation by Universities/Institutes
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Pipeline Products Glance
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Products under Development by Companies
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Products under Investigation by Universities/Institutes
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Companies Involved in Therapeutics Development
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Therapeutics Assessment
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Dormant Projects
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Discontinued Products
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity
Product Development Milestones
Type 1 diabetes (Juvenile Diabetes)
Type 2 Diabetes
Obesity

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016
Number of Products under Development for Type 2 Diabetes, H2 2016
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2016
Number of Products under Development for Obesity, H2 2016
Number of Products under Development for Obesity - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Development by Companies, H2 2016 (Contd..17)
Number of Products under Development by Companies, H2 2016 (Contd..18)
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Development by Companies, H2 2016 (Contd..29)
Products under Development by Companies, H2 2016 (Contd..30)
Products under Development by Companies, H2 2016 (Contd..31)
Products under Development by Companies, H2 2016 (Contd..32)
Products under Development by Companies, H2 2016 (Contd..33)
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AbGenomics International, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH and Co KG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ConjuChem, LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by enGene, Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Private Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Strongbridge Biopharma plc , H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H2 2016
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016
Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H2 2016
Type 2 Diabetes - Pipeline by Adocia, H2 2016
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H2 2016
Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H2 2016
Type 2 Diabetes - Pipeline by AFFiRiS AG, H2 2016
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H2 2016

List of Chart

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H2 2016
Number of Products under Development for Type 2 Diabetes, H2 2016
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2016
Number of Products under Development for Obesity, H2 2016
Number of Products under Development for Obesity - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Diabetic Macular Edema Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling.  Due to such swelling, a person’s central eye vision gets distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). Diabetic macular edema is the major reason for loss of vision in patients suffering from diabetic retinopathy. Di...